UCLA test predicts which prostate cancer patients are most likely to develop long-term side effects from radiation therapy

FDA approves prostate cancer imaging agent Gozellix

FDA approved Gozellix (TLX007-CDx, kit for the preparation of gallium-68 (68Ga) gozetotide injection), a next-generation PSMA-PET imaging agent for prostate cancer.

March 28, 2025

Vol.51 No.12

In the Archives

In 1990, “political oncologist” Helene Brown predicted the future. Did she get it right?

When Helene Brown, a cancer control pioneer who jokingly described herself as “the first in a long line of political oncologists,” delivered the keynote address at the Oncology Nursing Society annual meeting in 1990, she set forth bold predictions for the ensuing 20 years of the field: appointments conducted over “computerphone,” major genetic breakthroughs, and universal healthcare.

Owen Witte awarded International Harrington Prize for Innovation in Medicine

The Harrington Discovery Institute at University Hospitals and the American Society for Clinical Investigation have awarded Owen Witte with the twelfth annual Harrington Prize for Innovation in Medicine.

March 21, 2025

Vol.51 No.11

In Brief

UCLA’s Theodore Scott Nowicki awarded $4.5M to advance cellular immunotherapies for solid tumors

Physician-scientist Theodore Scott Nowicki, an assistant professor-in-residence of pediatric hematology/oncology and microbiology, immunology, and molecular genetics at the David Geffen School of Medicine at UCLA, has been awarded a $4.5 million R37 MERIT Award to help improve the effectiveness of cellular therapies for solid tumors.

March 21, 2025

Vol.51 No.11

Clinical Roundup

AI tool helps predict who will benefit from focal therapy for prostate cancer, study shows

A study led by UCLA investigators shows that AI could play a key role in improving treatment outcomes for patients with prostate cancer by helping physicians determine who is most likely to benefit from partial gland cryoablation, a minimally invasive procedure that treats localized prostate tumors.

March 21, 2025

Vol.51 No.11

Clinical Roundup

Shorter radiation treatment approach shows safety and efficacy for early-stage prostate cancer

A new large-scale study, co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators, provides the strongest evidence yet that a shorter, standard-dose course radiation treatment is equally as effective as conventional radiotherapy for prostate cancer, without compromising patient safety.

March 21, 2025

Vol.51 No.11

UCLA test predicts which prostate cancer patients are most likely to develop long-term side effects from radiation therapy

YOU MAY BE INTERESTED IN

FDA approves prostate cancer imaging agent Gozellix

In 1990, “political oncologist” Helene Brown predicted the future. Did she get it right?

Owen Witte awarded International Harrington Prize for Innovation in Medicine

UCLA’s Theodore Scott Nowicki awarded $4.5M to advance cellular immunotherapies for solid tumors

AI tool helps predict who will benefit from focal therapy for prostate cancer, study shows

Shorter radiation treatment approach shows safety and efficacy for early-stage prostate cancer

Renew today!

Subscriber content

Never miss an issue!

Login